RP-832c

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRP-832c
Drug Alias NameRP-832cAUR-300
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionFibroblast activation protein alpha antagonists
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsFibrosisScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRiptide Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesAurinia Pharmaceuticals IncRiptide Bioscience Inc
Inactive CompaniesN/A
Active IndicationsFibrosisScleroderma, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A